<DOC>
	<DOCNO>NCT00699504</DOCNO>
	<brief_summary>To assess safety cangrelor cardiac repolarization measure electrocardiogram ( ECG ) therapeutic supratherapeutic dos .</brief_summary>
	<brief_title>Assess Effect Cangrelor Therapeutic Dose Supratherapeutic Dose Level QT/QTc Interval Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cangrelor</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>1 . Male non pregnant female 18 year 45 year age , inclusive . 2 . Female subject childbearing potential ( ie , undergone hysterectomy , tubal ligation , postmenopausal least 12 consecutive month , whose partner undergone vasectomy ) must commit either abstain continuously heterosexual sexual contact use two method birth control , one must barrier method ( eg , hormonal contraception , latex condom , diaphragm , cervical cap ) , begin screen throughout study participation . 3 . A body mass index ( BMI ) 19 kg/m2 28 kg/m2 , inclusive . 4 . Agrees abstain alcohol consumption least 3 day first dose study drug throughout study participation . 5 . Agrees abstain caffeine nicotine replacement therapy day study drug administration serial ECG measurement . 6 . No clinically significant abnormal finding physical examination , ECG , blood pressure , heart rate , medical history , clinical laboratory test screen . 7 . Serum magnesium potassium level within normal range per local lab time screen . 8 . Healthy volunteer determine screening assessment . 9 . Willing able comply trial requirement . 10 . Provide write informed consent initiation study related procedure . 1 . Known suspected pregnancy . 2 . Increased bleed risk : ischemic stroke within last year previous hemorrhagic stroke , tumor , intracranial aneurysm ; recent ( &lt; 1 month ) trauma major surgery ; active bleeding . 3 . Impaired hemostasis : know International Normalized Ratio ( INR ) &gt; 1.5 ; past present bleed disorder ( include congenital bleeding disorder von Willebrand 's disease hemophilia , acquire bleeding disorder , unexplained clinically significant bleed disorder ) , thrombocytopenia ( platelet count &lt; 100,000/ÂµL ) . 4 . Sustained supine systolic blood pressure &gt; 140 mmHg &lt; 100 mmHg diastolic blood pressure &gt; 95 mmHg &lt; 60 mmHg screen baseline . Blood pressure may retested twice supine position interval 5 minute . Blood pressure consider sustain either systolic diastolic pressure exceed state limit three assessment . 5 . Resting pulse rate &lt; 50 beat per minute ( bpm ) &gt; 100 bpm . 6 . Abnormality 12 lead ECG , opinion investigator , increase risk participate study , correct QT interval ( QTcB QTcF ) &gt; 450 millisecond . The following conduction abnormality may confound QTc analysis avoid : PR &gt; 220 millisecond , second third degree atrioventricular ( AV ) block , intraventricular conduction defect ( IVCD ) QRS &gt; 120 millisecond , complete leave bundle branch block ( LBBB ) , leave anterior fascicular block ( LAFB ) , leave posterior fascicular block ( LPFB ) , right bundle branch block ( RBBB ) , Wolff Parkinson White syndrome ( WPW ) ( WPW define PR &gt; 120 millisecond , P axis 1 90 , QRS complex &gt; 120 millisecond , delta wave present ) . 7 . Personal history long QT syndrome , heart failure , hypokalemia . 8 . Personal history unexplained syncope . 9 . Immediatefamily history long QT syndrome . 10 . Family history sudden death . 11 . Concurrent medical condition , therapy , medication affect ECG , especially prolongation QT/QTc interval . 12 . Use prescription counter ( pseudoephedrine contain cold medicine ) medication , include herbal remedy health supplement , know prolong QT/QTc interval within 14 day prior start study throughout study participation . 13 . Intention use prescription ( thyroid hormone replacement dose regimen replacement therapy stable least 4 week prior screen expect remain stable study participation hormonal contraception ) counter medication , include herbal remedy health supplement , within 14 day initial dose study drug throughout study participation . If situation arises , inclusion otherwise suitable volunteer may discretion investigator discussion Sponsor . 14 . Current smoker subject discontinue smoke few 6 month prior study entry . 15 . Donation blood plasma last month , donation &gt; 400 mL blood within 3 month precede study drug administration . 16 . Clinically significant abnormality clinical laboratory test result . 17 . Positive virology screen human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C. 18 . Positive urine test drug abuse alcohol . 19 . Clinically significant disease condition affect major organ system , include , limited , gastrointestinal , renal , hepatic , bronchopulmonary , neurological , metabolic cardiovascular disease . 20 . Allergy , hypersensitivity , contraindication quinolone antibiotic , cangrelor , excipients . 21 . History multiple adverse drug allergy origin . 22 . Deemed investigator , reason , inappropriate study , include subject unable communicate cooperate investigator . 23 . Treatment investigational agent device within 30 day precede randomization , plan use investigational drug device study participation , previous enrollment trial . 24 . Inability give inform consent high likelihood unable complete necessary confinement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>ECG</keyword>
	<keyword>QT</keyword>
	<keyword>Effect study drug healthy volunteer</keyword>
</DOC>